Category : Nutrition

Prof. Patrice Cani, of Belgium’s Université catholique de Louvain, is involved in the Metabolism and Nutrition research group of the Louvain Drug Research Institute. He investigates the role of the gut microbiota in the development of metabolic disorders: obesity, type 2 diabetes and low-grade inflammation. He aims to uncover the mechanisms involved in the gut-to-liver and in the gut-to-adipose tissue…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

Prof. Patrice Cani, of Belgium’s Université catholique de Louvain, is involved in the Metabolism and Nutrition research group of the Louvain Drug Research Institute. He investigates the role of the gut microbiota in the development of metabolic disorders: obesity, type 2 diabetes and low-grade inflammation. He aims to uncover the mechanisms involved in the gut-to-liver and in the gut-to-adipose tissue…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

At the occasion of the "New therapies in coeliac disease" conference hosted by Columbia University in New-York on March 20, 2014, Dr. Elena Verdú, our expert in Nutrition, is sharing with us the last trends in research in the field of Coeliac Disease (CeD), introducing the idea of a role of probiotics in the treatment of CeD. Presence of intestinal dysbiosis…

Elena Verdú
Dr. Verdu’s research has focused on the pathophysiology of inflammatory and functional gastrointestinal disorders. She undertook clinical research training at the University of Lausanne, Switzerland, where she studied the interaction between chronic infection with Helicobacter pylori and gastritis in humans and the possible therapeutic role of probiotic bacteria. Her PhD studies in the Institute of Microbiology and Gnotobiology at the Czech Academy of Science and University of Lausanne focused on the effect of bacterial antigens in animal models of inflammatory bowel disease. As a post-doctoral fellow at McMaster University she gained experience with animal models of gut functional diseases and investigated the mechanisms of action of probiotic bacteria. As a member of the Farncombe Family Digestive Health Research Institute at McMaster University, Dr. Verdu investigates host-microbial and dietary interactions in the context of celiac disease, irritable bowel syndrome and inflammatory bowel disease. She has been honored with the New Investigator Award (Canadian Celiac Association), the New Investigator Award (Functional Gut-Brain Research Group, USA) and the Campbell Research Award in celiac disease (Canadian Celiac Association). The American Gastroenterology Association and the Canadian Association of Gastroenterology have awarded her the “Master’s in Gastroenterology Award” for basic science and “Young Investigator’s Award”, respectively. She is Associate Professor at the Division of Gastroenterology, Dep. of Medicine at McMaster University and currently directs the Axenic Gnotobiotic Unit at McMaster.

At the occasion of the "New therapies in coeliac disease" conference hosted by Columbia University in New-York on March 20, 2014, Dr. Elena Verdú, our expert in Nutrition, is sharing with us the last trends in research in the field of Coeliac Disease (CeD), introducing the idea of a role of probiotics in the treatment of CeD. Presence of intestinal dysbiosis…

Elena Verdú
Dr. Verdu’s research has focused on the pathophysiology of inflammatory and functional gastrointestinal disorders. She undertook clinical research training at the University of Lausanne, Switzerland, where she studied the interaction between chronic infection with Helicobacter pylori and gastritis in humans and the possible therapeutic role of probiotic bacteria. Her PhD studies in the Institute of Microbiology and Gnotobiology at the Czech Academy of Science and University of Lausanne focused on the effect of bacterial antigens in animal models of inflammatory bowel disease. As a post-doctoral fellow at McMaster University she gained experience with animal models of gut functional diseases and investigated the mechanisms of action of probiotic bacteria. As a member of the Farncombe Family Digestive Health Research Institute at McMaster University, Dr. Verdu investigates host-microbial and dietary interactions in the context of celiac disease, irritable bowel syndrome and inflammatory bowel disease. She has been honored with the New Investigator Award (Canadian Celiac Association), the New Investigator Award (Functional Gut-Brain Research Group, USA) and the Campbell Research Award in celiac disease (Canadian Celiac Association). The American Gastroenterology Association and the Canadian Association of Gastroenterology have awarded her the “Master’s in Gastroenterology Award” for basic science and “Young Investigator’s Award”, respectively. She is Associate Professor at the Division of Gastroenterology, Dep. of Medicine at McMaster University and currently directs the Axenic Gnotobiotic Unit at McMaster.

Dr Tom van den Bogert focused his research on small intestinal microbiota combining cutting edge omics method like metagenomics. He accepted to give us more detailed information about his work conducted in TIFN framework. We advise our readers to follow him on twitter @TomvandenBogert. What is your background? My studies started in Rotterdam where I obtained a bachelor's degree with a specialization in…

GMFH Editing Team
GMFH Editing Team

Dr Tom van den Bogert focused his research on small intestinal microbiota combining cutting edge omics method like metagenomics. He accepted to give us more detailed information about his work conducted in TIFN framework. We advise our readers to follow him on twitter @TomvandenBogert. What is your background? My studies started in Rotterdam where I obtained a bachelor's degree with a specialization in…

GMFH Editing Team
GMFH Editing Team

Prof. Jeffrey Gordon was invited to give a TED talk at the TEDxGatewayArch. His talk introduces the ideas of microbiota and microbiome, a new view to our connection to the microbial world as humans. He goes on detailing how our microbiome is for us a new way of considering our human evolution: it's a part of evolution that goes much…

GMFH Editing Team
GMFH Editing Team

Prof. Jeffrey Gordon was invited to give a TED talk at the TEDxGatewayArch. His talk introduces the ideas of microbiota and microbiome, a new view to our connection to the microbial world as humans. He goes on detailing how our microbiome is for us a new way of considering our human evolution: it's a part of evolution that goes much…

GMFH Editing Team
GMFH Editing Team

Dr Elena Verdú's lab seeks to understand the complex pathophysiology of gastrointestinal disease, with a focus on microbiota-diet interactions, to identify novel therapeutic targets for these disorders.     1/ What strikes you most in the evolution of research on gut microbiota and why? One interesting aspect relates to the way we have approached the study of the microbiota. We…

GMFH Editing Team
GMFH Editing Team

Dr Elena Verdú's lab seeks to understand the complex pathophysiology of gastrointestinal disease, with a focus on microbiota-diet interactions, to identify novel therapeutic targets for these disorders.     1/ What strikes you most in the evolution of research on gut microbiota and why? One interesting aspect relates to the way we have approached the study of the microbiota. We…

GMFH Editing Team
GMFH Editing Team

This basic research sought to better understand how soluble dietary fibers exert their beneficial effect on body weight and glucose control. The researchers show that two short-chain fatty acids, which are produced by fermentation of soluble fiber by gut bacteria, activate intestinal gluconeogenesis (IGN) gene expression through different, but complementary, mechanisms. One of the mechanisms activates IGN gene expression through a…

GMFH Editing Team
GMFH Editing Team

This basic research sought to better understand how soluble dietary fibers exert their beneficial effect on body weight and glucose control. The researchers show that two short-chain fatty acids, which are produced by fermentation of soluble fiber by gut bacteria, activate intestinal gluconeogenesis (IGN) gene expression through different, but complementary, mechanisms. One of the mechanisms activates IGN gene expression through a…

GMFH Editing Team
GMFH Editing Team

Filipe De Vadder is a molecular biologist in Gilles Mithieux group and published recently an important article in Cell journal which illustrate how gut microbiota fermentation product could impact neural communication. He accepted for GMFH to give us some highlights. 1) What is the context of this study? Dietary fiber has long been known for its beneficial effects on health,…

GMFH Editing Team
GMFH Editing Team

Filipe De Vadder is a molecular biologist in Gilles Mithieux group and published recently an important article in Cell journal which illustrate how gut microbiota fermentation product could impact neural communication. He accepted for GMFH to give us some highlights. 1) What is the context of this study? Dietary fiber has long been known for its beneficial effects on health,…

GMFH Editing Team
GMFH Editing Team

Machiels et al. recently described that the composition of the faecal microbiota of patients suffering from ulcerative colitis differs from that of healthy individuals: they found a reduction in two well-known butyrate-producing bacteria of the Firmicutes phylum, Roseburia hominis and Faecalibacterium prausnitzii. This has been confirmed in other studies. The dysbiosis found in the two inflammatory bowel diseases (IBD) i.e. Crohn’s…

Philippe Marteau
Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.

Machiels et al. recently described that the composition of the faecal microbiota of patients suffering from ulcerative colitis differs from that of healthy individuals: they found a reduction in two well-known butyrate-producing bacteria of the Firmicutes phylum, Roseburia hominis and Faecalibacterium prausnitzii. This has been confirmed in other studies. The dysbiosis found in the two inflammatory bowel diseases (IBD) i.e. Crohn’s…

Philippe Marteau
Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.

One year at a glance is the compilation of the most relevant and popular content on gut microbiota as published on the GMFH website.   The topic is rapidly growing across all fields of expertise and questions it raises are endless. It seems that hardly a day goes without gut microbiota being related to the health status (enterotypes, second genotype, ageing),…

GMFH Editing Team
GMFH Editing Team

One year at a glance is the compilation of the most relevant and popular content on gut microbiota as published on the GMFH website.   The topic is rapidly growing across all fields of expertise and questions it raises are endless. It seems that hardly a day goes without gut microbiota being related to the health status (enterotypes, second genotype, ageing),…

GMFH Editing Team
GMFH Editing Team

The team of Jeffrey Gordon (Ridaura et al. Science 2013) published that the phenotype of obesity (increased adiposity) of an obese twin in a discordant twin pair is transmissible. In other words, they found that mice receiving an obese twin’s fecal microbiota display a greater fat mass than the mice receiving lean twin’s gut microbes. Cohousing is widely used in…

Patrice D. Cani
Professor Patrice D. Cani is researcher from the Belgian Fund for Scientific Research (FRS-FNRS), group leader in the Metabolism and Nutrition research group at the Louvain Drug Research Institute (LDRI) from the Université catholique de Louvain (UCL), Brussels, Belgium, and WELBIO (Walloon Excellence in Lifesciences and BIOtechnology) investigator. He is currently member of several international associations, he is member of the Alumni College from the Royal Belgian Academy of Sciences, and he has been elected in the board of directors of the LDRI (UCL). Patrice D. Cani has a M.Sc. in Nutrition and another M.Sc. in health Sciences, he is registered dietitian and PhD in Biomedical Sciences. His main research interests are the investigation of the role of the gut microbiota in the development of metabolic disorders, such as obesity, type 2 diabetes and low grade inflammation. More specifically, he is investigating the interactions between the gut microbiota, the host and specific biological systems such as the endocannabinoid system and the innate immune system in the context of obesity, type 2 diabetes and metabolic inflammation. Prof Cani is author and co-author of more than 110 scientific research papers published in peer-reviewed international journals, conferences and book chapters.

The team of Jeffrey Gordon (Ridaura et al. Science 2013) published that the phenotype of obesity (increased adiposity) of an obese twin in a discordant twin pair is transmissible. In other words, they found that mice receiving an obese twin’s fecal microbiota display a greater fat mass than the mice receiving lean twin’s gut microbes. Cohousing is widely used in…

Patrice D. Cani
Professor Patrice D. Cani is researcher from the Belgian Fund for Scientific Research (FRS-FNRS), group leader in the Metabolism and Nutrition research group at the Louvain Drug Research Institute (LDRI) from the Université catholique de Louvain (UCL), Brussels, Belgium, and WELBIO (Walloon Excellence in Lifesciences and BIOtechnology) investigator. He is currently member of several international associations, he is member of the Alumni College from the Royal Belgian Academy of Sciences, and he has been elected in the board of directors of the LDRI (UCL). Patrice D. Cani has a M.Sc. in Nutrition and another M.Sc. in health Sciences, he is registered dietitian and PhD in Biomedical Sciences. His main research interests are the investigation of the role of the gut microbiota in the development of metabolic disorders, such as obesity, type 2 diabetes and low grade inflammation. More specifically, he is investigating the interactions between the gut microbiota, the host and specific biological systems such as the endocannabinoid system and the innate immune system in the context of obesity, type 2 diabetes and metabolic inflammation. Prof Cani is author and co-author of more than 110 scientific research papers published in peer-reviewed international journals, conferences and book chapters.